ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1567

A Functional Genomic Screen of Rheumatoid Arthritis Risk Genes in Primary Human T Cells Reveals DDX6 As a Negative Modulator of Cytokine Expression

Rumey Ishizawar1, Chantel Lester2, Jing Cui3, John Doench4, Robert Plenge5 and Michael Brenner6, 1Division of Rheumatology, Allergy, and Immunology and Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, NC, 2Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 3Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 4Broad Institute of MIT and Harvard, Cambridge, MA, 5Genetics & Pharmacogenomics, Merck Research Laboratories, Merck & Co., Boston, MA, 6Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: cytokines and rheumatoid arthritis (RA), GWAS, T cells

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Rheumatoid Arthritis – Human Etiology and Pathogenesis - Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:  In rheumatoid arthritis (RA), genome-wide association studies have identified over 100 risk alleles. A major challenge is identifying causal genes in RA risk loci. As RA risk loci are enriched with many genes expressed in CD4+ memory T cells, our objective was to determine which risk-associated genes regulate T cell cytokine expression and dissect relevant biologic pathways important in RA development.

Methods:  A lentiviral small hairpin RNA (shRNA) library targeting ~40 RA risk genes was generated. Each RA risk gene was targeted by 5-8 shRNA clones. The shRNA was used to disrupt expression of RA risk genes in primary human CD4+ memory T cells, which were negatively isolated from healthy donor peripheral blood mononuclear cells. Primary human CD4+ memory T cells underwent infection, selection and then T cell receptor activation to promote cytokine expression. Enzyme-linked immunosorbent assay (ELISA) was used to measure expression of IL-10, IL-13, IL-17A and IFN- γ in culture media. Generation of relative cytokine level per cell number, line of best fit and additional analysis was performed using SAS v9.3. Rank order system was generated to identify genes that modulated cytokine expression in comparison to control shRNA. Genes identified in the primary screen were reassessed in a secondary screen and then further validated.

Results:  DDX6, a member of the DEAD-box helicase and post-transcriptional regulator family, was identified in our screen as a negative regulator of IL-10, IL-13, IL-17A and IFN-γ expression in activated CD4+ T cells. DDX6 silencing in CD4+ T cells increased cytokine expression, validating the screen findings. In addition, DDX6 mRNA levels were elevated in resting CD4+ T cells but decreased when CD4+T cells are functionally activated. Loss of expression inversely correlated with cytokine expression. We then demonstrated that DDX6 (p54/Rck) physically interacts with cytokine mRNA during transcriptionally quiescent states using RNA immunopreciptation.

Conclusion: Our experimental approach provides a systematic strategy to functionally differentiate candidate RA susceptibility genes based on relevant biological pathways. Specifically, we identified DDX6 as an important regulator of effector function of primary human CD4+ T cells.


Disclosure: R. Ishizawar, EMD Millipore, 3; C. Lester, None; J. Cui, None; J. Doench, None; R. Plenge, Merck Pharmaceuticals, 3; M. Brenner, Roche Pharmaceuticals, 5.

To cite this abstract in AMA style:

Ishizawar R, Lester C, Cui J, Doench J, Plenge R, Brenner M. A Functional Genomic Screen of Rheumatoid Arthritis Risk Genes in Primary Human T Cells Reveals DDX6 As a Negative Modulator of Cytokine Expression [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/a-functional-genomic-screen-of-rheumatoid-arthritis-risk-genes-in-primary-human-t-cells-reveals-ddx6-as-a-negative-modulator-of-cytokine-expression/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-functional-genomic-screen-of-rheumatoid-arthritis-risk-genes-in-primary-human-t-cells-reveals-ddx6-as-a-negative-modulator-of-cytokine-expression/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology